Albert David Limited has accepted the resignation of Dr. Kuntal Ganguly from his position as Head of Research and Development. The resignation is effective from the close of business hours on August 5, 2026. The company cited personal reasons for the departure in its disclosure to stock exchanges.

The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para-A of Part-A of Schedule III to the said Regulations. The disclosure was submitted to both the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 6, 2026.

Resignation Details

The company provided specific details regarding the change in senior managerial personnel in Annexure-A of the filing:

Lalit Lohia, Company Secretary and Compliance Officer of Albert David Limited, signed the disclosure. A copy of the resignation email from the HR Department was enclosed as Annexure-B.

Company Response

In its communication to the exchanges, Albert David Limited expressed appreciation for the services rendered by Dr. Kuntal Ganguly during his tenure with the company. The filing confirmed that there are no disclosed relationships between directors related to this change, as it pertains to a senior managerial position rather than a directorship.

Albert David Limited reported a net profit of ₹3,199.78 lakh for the quarter ended June 30, 2026, reversing a net loss of ₹2,143.44 lakh in the previous quarter. The pharmaceutical manufacturer’s revenue from operations rose 43.6% year-on-year to ₹10,133.55 lakh, reflecting robust demand and operational efficiency. This profit marks a sharp recovery from the consolidated loss of ₹149.47 lakh in FY26, signaling a return to profitability for the Kotahari Group unit.

The Board of Directors approved the unaudited financial results at a meeting held on August 6, 2026, in Kolkata. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, L.B. Jha & Co., LLP, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates under Indian Accounting Standard 34 (Ind AS 34) for interim financial reporting.

Financial Performance Highlights

Revenue from operations increased to ₹10,133.55 lakh in Q1FY26 from ₹7,056.64 lakh in the same period last year. Total income for the quarter stood at ₹12,929.78 lakh, aided by other income of ₹2,796.23 lakh, compared to a negative other income of ₹2,483.84 lakh in Q4FY26. Total expenses were contained at ₹9,350.38 lakh, down slightly from ₹8,625.88 lakh in the prior quarter but higher than ₹8,416.43 lakh in Q1FY25.

What the Numbers Show

The most significant driver of the quarterly turnaround was the reversal in other income. While revenue growth contributed positively, the shift from negative other income in Q4FY26 to positive other income in Q1FY26 substantially boosted total income. Additionally, employee benefit expenses decreased to ₹2,555.24 lakh from ₹2,843.02 lakh in Q1FY25, indicating improved cost management despite the rise in material costs to ₹1,833.19 lakh from ₹1,324.80 lakh year-on-year.

Tax expenses for the quarter totaled ₹379.62 lakh, comprising current tax of ₹354.78 lakh and deferred tax of ₹259.83 lakh, partially offset by an income tax credit for earlier years of ₹234.99 lakh. The company’s paid-up equity share capital remained unchanged at ₹570.72 lakh. Earnings per share stood at ₹56.07, a stark contrast to the loss per share of ₹37.56 in the previous quarter.